ATE68014T1 - Die synthese eines proteins mittels eines identifizierungspeptids. - Google Patents

Die synthese eines proteins mittels eines identifizierungspeptids.

Info

Publication number
ATE68014T1
ATE68014T1 AT85300432T AT85300432T ATE68014T1 AT E68014 T1 ATE68014 T1 AT E68014T1 AT 85300432 T AT85300432 T AT 85300432T AT 85300432 T AT85300432 T AT 85300432T AT E68014 T1 ATE68014 T1 AT E68014T1
Authority
AT
Austria
Prior art keywords
identification peptide
functional protein
protein
hybrid polypeptide
terminal
Prior art date
Application number
AT85300432T
Other languages
English (en)
Inventor
Thomas P Hopp
Susan L Bektesh
Iii Paul J Conlon
Carl J March
Original Assignee
Immunex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24293537&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE68014(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Immunex Corp filed Critical Immunex Corp
Application granted granted Critical
Publication of ATE68014T1 publication Critical patent/ATE68014T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/28—Bound to a nonpeptide drug, nonpeptide label, nonpeptide carrier, or a nonpeptide resin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AT85300432T 1984-01-24 1985-01-23 Die synthese eines proteins mittels eines identifizierungspeptids. ATE68014T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US06/573,825 US4703004A (en) 1984-01-24 1984-01-24 Synthesis of protein with an identification peptide
EP85300432A EP0150126B1 (de) 1984-01-24 1985-01-23 Die Synthese eines Proteins mittels eines Identifizierungspeptids

Publications (1)

Publication Number Publication Date
ATE68014T1 true ATE68014T1 (de) 1991-10-15

Family

ID=24293537

Family Applications (1)

Application Number Title Priority Date Filing Date
AT85300432T ATE68014T1 (de) 1984-01-24 1985-01-23 Die synthese eines proteins mittels eines identifizierungspeptids.

Country Status (5)

Country Link
US (1) US4703004A (de)
EP (1) EP0150126B1 (de)
JP (1) JPH074255B2 (de)
AT (1) ATE68014T1 (de)
DE (1) DE3584260D1 (de)

Families Citing this family (178)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0162898A4 (de) * 1983-11-14 1987-07-23 Chiron Corp Interleukin-2-erzeugung unter verwendung klonierter gene für interleukin-2 und hefe alpha-faktor.
US5691181A (en) * 1984-08-21 1997-11-25 Celltech Limited DNA encoding lipase from human gastric mucosal tissue
US6808901B1 (en) * 1984-09-03 2004-10-26 Celltech R&D Limited Production of chimeric antibodies
GB8422238D0 (en) * 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US5853978A (en) * 1985-12-04 1998-12-29 Genentech, Inc. Molecularly cloned acquired immunodeficiency syndrome polypeptides and methods of use
US6534285B1 (en) * 1984-12-24 2003-03-18 Genentech, Inc. Molecularly cloned acquired immunodeficiency syndrome polypeptides and their methods of use
EP0195680A3 (de) * 1985-03-21 1987-06-10 Immunex Corporation Proteinsynthese mit einem Identifizierungspeptid
DE3686365T3 (de) * 1985-06-20 2000-07-27 Fujisawa Pharmaceutical Co., Ltd. Herstellungsverfahren für humanes atriales natriuretisches Polypeptid.
EP0207044A1 (de) * 1985-06-20 1986-12-30 Monsanto Company Freisetzung von Peptiden aus Polypeptiden
US4828799A (en) * 1985-06-26 1989-05-09 Research Corporation Therapeutic drug monitoring and analyte determination utilizing micellar chromatography
FR2594846B1 (fr) * 1986-02-21 1989-10-20 Genetica Procede de preparation de la serum albumine humaine mature
SE8601940D0 (sv) * 1986-04-25 1986-04-25 Kabigen Ab Preparation of fused proteins, antibodies and processes therefor
US5011912A (en) * 1986-12-19 1991-04-30 Immunex Corporation Hybridoma and monoclonal antibody for use in an immunoaffinity purification system
US4851341A (en) * 1986-12-19 1989-07-25 Immunex Corporation Immunoaffinity purification system
US5013653A (en) * 1987-03-20 1991-05-07 Creative Biomolecules, Inc. Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage
US5215896A (en) * 1987-03-20 1993-06-01 Creative Biomolecules, Inc. Leader sequences for the production of recombinant proteins
US5200509A (en) * 1987-04-06 1993-04-06 Celtrix Pharmaceuticals, Inc. Human somatomedin carrier protein subunits and process for producing them; recombinant DNA molecules, hosts, processes and human somatomedin carrier protein-like polypeptides
FR2615528B1 (fr) * 1987-05-18 1991-05-24 Pasteur Institut Procede de production d'un polypeptide ayant des proprietes choisies determinees, dans un organisme-hote transforme par un adn recombinant contenant des sequences nucleiques codant pour ce polypeptide et pour une proteine affine d'ose
ZA887773B (en) 1987-10-26 1989-07-26 Immunex Corp Interleukin-7
AU2635088A (en) * 1987-12-04 1989-06-08 Du Pont Merck Pharmaceutical Company, The Immobilized interleukin 2 and interleukin 2 containing a carboxyl-terminal extension
US4931498A (en) * 1988-02-25 1990-06-05 Purdue Research Foundation Immobilized artificial membranes
US4927879A (en) * 1988-02-25 1990-05-22 Purdue Research Foundation Method for solid phase membrane mimetics
USRE39760E1 (en) * 1988-03-31 2007-08-07 International Bio-Immune Systems Inc. Monoclonal antibodies against human colon carcinoma-associated antigens and uses therefor
US5262322A (en) * 1988-06-24 1993-11-16 Genentech, Inc. Host transformed with yeast gene and ubiquitin/polypeptide fusions
US5156968A (en) * 1988-06-24 1992-10-20 Genentech, Inc. Purified yeast ubiquitin hydrolase
US5108919A (en) * 1988-06-24 1992-04-28 Genentech, Inc. Dna sequences encoding yeast ubiquitin hydrolase
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
WO1990005183A1 (en) 1988-10-31 1990-05-17 Immunex Corporation Interleukin-4 receptors
ZA902949B (en) * 1989-05-05 1992-02-26 Res Dev Foundation A novel antibody delivery system for biological response modifiers
EP0406857B1 (de) * 1989-07-07 1995-05-24 Takeda Chemical Industries, Ltd. Proteine und deren Herstellung
US7413537B2 (en) * 1989-09-01 2008-08-19 Dyax Corp. Directed evolution of disulfide-bonded micro-proteins
AU646695B2 (en) 1990-04-09 1994-03-03 Immunex Corporation Isolated viral protein cytokine antagonists
US5595887A (en) * 1990-07-16 1997-01-21 Bionebraska, Inc. Purification directed cloning of peptides using carbonic anhydrase as the affinity binding segment
WO1992006191A1 (en) * 1990-09-28 1992-04-16 Protein Engineering Corporation Proteinaceous anti-dental plaque agents
JPH07108232B2 (ja) * 1990-10-09 1995-11-22 エム・ディ・リサーチ株式会社 ペプチド又は蛋白質の製造方法
US6083686A (en) * 1990-10-26 2000-07-04 Johnson & Johnson Clinical Diagnostic Systems, Inc. Increased production of Thermus aquaticus DNA polymerase in E. coli
HUT69963A (en) * 1990-12-13 1995-09-28 Upjohn Co Non-naturally-occuring fusion proteins and process for preparing them
US5270197A (en) * 1990-12-20 1993-12-14 The Children's Medical Center Corporation Cells expressing a substantial number of surface high affinity HBGF receptors but relatively few low affinity HBGF binding sites and system for assaying binding to HBGF receptor
DE69233769D1 (de) * 1991-03-01 2009-09-24 Dyax Corp Chimäres Protein mit Mikroprotein mit zwei oder mehr Disulfidbindungen und Ausgestaltungen davon
US5712381A (en) * 1994-10-19 1998-01-27 Genetics Institute, Inc. MADD, a TNF receptor death domain ligand protein
US5852173A (en) * 1994-10-19 1998-12-22 Genetics Institute, Inc. TNF receptor death ligand proteins and inhibitors of ligand binding
US5731425A (en) * 1994-10-28 1998-03-24 Eastman Kodak Company Polypeptide surface marker for cells
AU4415796A (en) * 1994-12-07 1996-06-26 Bionebraska, Inc. Production of c-terminal amidated peptides from recombinant protein constructs
US5795966A (en) 1995-02-22 1998-08-18 Immunex Corp Antagonists of interleukin-15
KR100510234B1 (ko) 1995-06-29 2005-11-25 임뮤넥스 코포레이션 세포소멸을 유도하는 시토킨
US6037149A (en) * 1995-08-24 2000-03-14 Magainin Pharmaceuticals Inc. DNA encoding human asthma associated factor 1
PT951551E (pt) 1996-12-23 2008-10-28 Immunex Corp Ligando para receptor activador de nf-kb, ligando membro da superfamília de tnf
US6913749B2 (en) 1998-11-02 2005-07-05 Resistentia Pharmaceuticals Ab Immunogenic polypeptides for inducing anti-self IgE responses
AU779689B2 (en) 1999-06-16 2005-02-03 Icos Corporation Human poly(ADP-ribose) polymerase 2 materials and methods
US6379903B1 (en) 1999-10-08 2002-04-30 Sigma-Aldrich Co. Purification of recombinant proteins fused to multiple epitopes
AU2001281464A1 (en) * 2000-03-13 2001-09-24 Monsanto Technology Llc Recombinant proteins containing repeating units
DK2223922T3 (en) 2000-04-25 2016-06-06 Icos Corp Inhibitors of HUMANPHOSPHATIDYL-inositol 3-KINASEDELTA
EP1939203B1 (de) 2000-04-25 2014-11-19 ICOS Corporation Hemmer der delta-Isoform der menschlichen Phosphatidyl-Inositol-3-Kinase
JP2004536554A (ja) * 2000-10-10 2004-12-09 ザ ボード オブ リージェンツ オブ ザ ユニヴァーシティー オブ オクラホマ Ｍｈｃ陽性細胞からの比較リガンドマッピング
US6756215B1 (en) 2000-10-20 2004-06-29 The United States Of America As Represented By The Secretary Of The Department Of Health & Human Services Functionalized TGF-β fusion proteins
ZA200305980B (en) 2001-02-12 2007-01-31 Res Dev Foundation Modified proteins, designer toxins, and methods of making thereof
DE10112851C1 (de) 2001-03-16 2002-10-10 Gsf Forschungszentrum Umwelt Semi-allogene Antitumor-Vakzine mit HLA-haplo-identischen Antigen-präsentierenden Zellen
MXPA03009059A (es) 2001-04-05 2004-10-15 Univ Nebraska Secuencias de nucleotidos reguladoras de alcohol oxidasa 1 para expresion de genes heterologos en levadura.
EP1401497B1 (de) * 2001-06-08 2012-01-11 Genaera Corporation Verfahren zur modulation von il-13
NZ530582A (en) 2001-07-17 2008-06-30 Res Dev Foundation Therapeutic agents comprising pro-apoptotic proteins, including granzyme, bax and TNF
US8088602B1 (en) 2001-12-05 2012-01-03 Elizabeth Gay Frayne Manipulation of RNA stability and protein synthesis using thio-phosphate
DE60329983D1 (de) 2002-03-01 2009-12-24 Monsanto Technology Llc Wachsestersynthase-dna-sequenz, protein und verwendungen davon
US7799561B2 (en) * 2002-06-12 2010-09-21 Sigma-Aldrich, Co. Affinity peptides and method for purification of recombinant proteins
EP1537415B1 (de) 2002-09-09 2008-12-17 Arbor Vita Corporation Verfahren zur diagnose von gebärmutterhalskrebs
US20050233307A1 (en) 2002-09-12 2005-10-20 Kyle Gee Site-specific labeling of affinity tags in fusion proteins
EP1588166A4 (de) * 2003-01-09 2007-06-27 Macrogenics Inc Doppelexpressionsvektorsystem für die antikörperexpression in bakteriellen und säugetierzellen
KR20060036901A (ko) * 2003-05-02 2006-05-02 시그마-알드리치컴퍼니 고상 세포 용해 및 포획 플랫폼
ATE554108T1 (de) 2003-07-25 2012-05-15 Amgen Inc Verfahren bezüglich ldcam und crtam
US20050178959A1 (en) * 2004-02-18 2005-08-18 Viorica Lopez-Avila Methods and compositions for assessing a sample by maldi mass spectrometry
EP1761540B1 (de) 2004-05-13 2016-09-28 Icos Corporation Chinazolinone als inhibitoren der humanen phosphatidylinosit-3-kinase delta
WO2006026248A1 (en) 2004-08-25 2006-03-09 Sigma-Aldrich Co. Compositions and methods employing zwitterionic detergent combinations
US7741053B2 (en) * 2005-05-13 2010-06-22 Sigma-Aldrich Co. Processes for purification of recombinant proteins
JP2008546392A (ja) * 2005-06-17 2008-12-25 バイオレクシス ファーマシューティカル コーポレーション 固定されたトランスフェリン融合タンパク質ライブラリー
US20070275416A1 (en) * 2006-05-16 2007-11-29 Gsf-Forschungszentrum Fuer Umwelt Und Gesundheit Gmbh Affinity marker for purification of proteins
EP1878744A1 (de) * 2006-07-13 2008-01-16 Max-Delbrück-Centrum für Molekulare Medizin (MDC) Epitope-Tag für an der Oberfläche exprimierte T-Zell Rezeptor Proteine, deren Anwendung und Verfahren zur Selection von Wirtszellen, die sie exprimieren
AU2007304883B2 (en) * 2006-10-04 2013-09-05 The University Of Queensland VLP based vaccine delivery system
JP5191390B2 (ja) 2006-10-11 2013-05-08 オリエンタル酵母工業株式会社 可溶型ｒａｎｋｌとエピトープタグの融合タンパク質を含む試薬
US20080118524A1 (en) * 2006-10-20 2008-05-22 Stefan Persson Anti-IgE Vaccines
ES2535358T3 (es) 2006-12-12 2015-05-08 Biorexis Pharmaceutical Corporation Bibliotecas de proteínas de fusión de transferrina
US8877206B2 (en) 2007-03-22 2014-11-04 Pds Biotechnology Corporation Stimulation of an immune response by cationic lipids
EP2142217B1 (de) * 2007-03-27 2014-11-05 Merck Sharp & Dohme Corp. Verfahren zum nachweis von automatisch aufbereitetem sezerniertem pcsk9
US7897369B2 (en) * 2007-08-27 2011-03-01 Regents Of The University Of Minnesota Isoprenoid wax ester synthases, isoprenoid acyl CoA-synthetases, and uses thereof
GEP20125635B (en) * 2007-11-13 2012-09-10 Icos Corp Inhibitors of human phosphatidyl-inositol 3-kinase delta
US20110020875A1 (en) * 2007-12-05 2011-01-27 University Of Georgia Research Foundation, Inc. Hydrogenase polypeptide and methods of use
AR070315A1 (es) 2008-02-07 2010-03-31 Merck & Co Inc Anticuerpos 1b20 antagonistas de pcsk9
WO2009114185A2 (en) 2008-03-12 2009-09-17 The Rockefeller University Methods and compositions for translational profiling and molecular phenotyping
AU2009236306B2 (en) 2008-04-17 2015-04-02 Pds Biotechnology Corporation Stimulation of an immune response by enantiomers of cationic lipids
WO2010011961A2 (en) 2008-07-25 2010-01-28 University Of Georgia Research Foundation, Inc. Prokaryotic rnai-like system and methods of use
WO2010033823A2 (en) 2008-09-18 2010-03-25 University Of Georgia Research Foundation, Inc. Methods and compositions for degrading pectin
US9404098B2 (en) * 2008-11-06 2016-08-02 University Of Georgia Research Foundation, Inc. Method for cleaving a target RNA using a Cas6 polypeptide
CN102272153B (zh) 2008-11-24 2015-04-15 德国慕尼黑亥姆霍兹研究中心健康和环境有限公司 高亲和力t细胞受体及其应用
CA2751762A1 (en) 2009-02-09 2010-08-12 Helmholtz Zentrum Muenchen Deutsches Forschungszentrum Fuer Gesundheit U Nd Umwelt (Gmbh) Repertoire of allo-restricted peptide-specific t cell receptor sequences and use thereof
EP2258719A1 (de) 2009-05-19 2010-12-08 Max-Delbrück-Centrum für Molekulare Medizin (MDC) Mehrfachziel-T-Zellen-Rezeptor
KR101790187B1 (ko) 2009-07-24 2017-10-25 이뮨 디자인 코포레이션 신드비스 바이러스 외피 당단백질로 가성형태화된 렌티바이러스 벡터
MX366890B (es) 2009-10-23 2019-07-30 Millennium Pharm Inc Moléculas de anticuerpo anti - gcc y composiciones y métodos relacionados.
WO2011056954A2 (en) 2009-11-04 2011-05-12 Regents Of The University Of Minnesota Haemophilus parasuis polypeptides and methods of use
WO2011066460A1 (en) * 2009-11-27 2011-06-03 Msdx, Inc. Methods of detecting or monitoring activity of an inflammatory or neurodegenerative condition
CN102762565A (zh) 2010-02-22 2012-10-31 弗·哈夫曼-拉罗切有限公司 吡啶并[3,2-d]嘧啶PI3δ抑制剂化合物及使用方法
US8734780B2 (en) 2010-06-04 2014-05-27 Medtronic, Inc. Methods for treating cardiac pacing conditions
CN103003279B (zh) 2010-07-14 2015-09-23 弗·哈夫曼-拉罗切有限公司 对PI3K P110δ具有选择性的嘌呤化合物及其使用方法
WO2012019061A2 (en) 2010-08-05 2012-02-09 Stem Centrx, Inc. Novel effectors and methods of use
US20130224191A1 (en) 2010-08-27 2013-08-29 Robert A. Stull Notum protein modulators and methods of use
WO2013119964A2 (en) 2012-02-08 2013-08-15 Stem Centrx, Inc. Identification and enrichment of cell subpopulations
WO2012031273A2 (en) 2010-09-03 2012-03-08 Stem Centrx, Inc. Novel modulators and methods of use
SG189212A1 (en) 2010-09-03 2013-05-31 Stem Centrx Inc Identification and enrichment of cell subpopulations
TWI655210B (zh) 2010-12-08 2019-04-01 艾伯維史坦森特瑞斯有限責任公司 新穎調節劑及其使用方法
WO2012098449A1 (en) 2011-01-17 2012-07-26 University Of Manitoba Methods for treating disorders that involve immunoglobulin a
US8673309B2 (en) * 2011-02-11 2014-03-18 Msdx, Inc. Methods for measuring high molecular weight complexes of fibrinogen with fibronectin and fibulin-1
US20120263754A1 (en) 2011-02-15 2012-10-18 Immune Design Corp. Methods for Enhancing Immunogen Specific Immune Responses by Vectored Vaccines
SA112330278B1 (ar) 2011-02-18 2015-10-09 ستيم سينتركس، انك. مواد ضابطة جديدة وطرق للاستخدام
WO2012154272A1 (en) 2011-02-25 2012-11-15 Wellstat Diagnostics, Llc Assays for detecting enzymatic activity
AU2012243039B2 (en) 2011-04-08 2017-07-13 Immune Design Corp. Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
US20130058947A1 (en) 2011-09-02 2013-03-07 Stem Centrx, Inc Novel Modulators and Methods of Use
RU2014138474A (ru) 2012-02-24 2016-04-10 СтемСентРкс, Инк. Новые модуляторы и способы применения
MX360245B (es) 2012-03-09 2018-10-26 Csl Behring Ag Composiciones que comprenden inmunoglobulinas de tipo secretor.
DK2831105T3 (da) 2012-03-28 2017-11-20 Univ Texas Tgf-type ii-type iii-receptorfusioner
DK2831095T3 (en) 2012-03-30 2019-02-18 Immune Design Corp LENTIVIRAL VECTOR PARTICLES WITH IMPROVED TRANSDUCTION EFFICIENCY FOR CELL EXPRESSING DC SIGN
US10286064B2 (en) 2012-06-15 2019-05-14 Pds Biotechnology Corporation Cationic lipid vaccine compositions and methods of use
US9587256B2 (en) 2012-09-06 2017-03-07 University Of Georgia Research Foundation, Inc. Sequestration of carbon dioxide with hydrogen to useful products
TWI672149B (zh) 2012-09-21 2019-09-21 美商Ｐｄｓ生技公司 改良之疫苗組成物及使用方法
US10036047B2 (en) 2013-06-10 2018-07-31 University Of Georgia Research Foundation, Inc. Methods for hydroxylating phenylpropanoids
US9353390B2 (en) 2013-06-13 2016-05-31 University Of Georgia Research Foundation, Inc. Genetically engineered microbes and methods for producing 4-hydroxycoumarin
CA2920376A1 (en) 2013-08-07 2015-02-12 Martin Blomberg JENSEN Methods and composition comprising denosumab or an antibody or antigen binding domain, fragment or derivative thereof, immunoreactive with a rankl/opgbp peptide for use in the treatment, prevention or alleviation of male infertility
CA2922529A1 (en) 2013-08-28 2015-03-05 Stemcentrx, Inc. Novel sez6 modulators and methods of use
PE20160674A1 (es) 2013-08-28 2016-07-21 Stemcentrx Inc Metodos de conjugacion de anticuerpos especificos de sitio y composiciones
WO2015123496A1 (en) 2014-02-14 2015-08-20 Immune Design Corp. Immunotherapy of cancer through combination of local and systemic immune stimulation
JP2017518737A (ja) 2014-04-21 2017-07-13 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． ＳＹＫ標的治療薬のための抗ｐＳＹＫ抗体分子及びその使用
MX378899B (es) 2014-05-26 2025-03-10 Academisch Ziekenhuis Leiden Proteinas prohemostaticas para el tratamiento de hemorragias.
KR20170032373A (ko) 2014-07-15 2017-03-22 이뮨 디자인 코포레이션 Tlr4 작용제 보조제 및 렌티바이러스 벡터를 이용한 프라임-부스트 요법
EP3012269A1 (de) 2014-10-20 2016-04-27 Erhard Hofer Zytokin-ähnliches 1 (CYTL1)-Protein und Verwendungen davon
DK3244911T3 (da) 2015-01-12 2019-12-16 Rigshospitalet Copenhagen Univ Hospital Fremgangsmåde til bestemmelse af en sandsynlig virkning af en behandling til forbedring af mandlig ufrugtbarhed
CA2976005A1 (en) 2015-02-06 2016-08-11 Cell Idx, Inc. Antigen-coupled immunoreagents
WO2016161004A1 (en) 2015-03-30 2016-10-06 The Board Of Regents Of The Nevada System Of Higher Educ. On Behalf Of The University Of Nevada, La Compositions comprising talens and methods of treating hiv
JP6924151B2 (ja) 2015-05-29 2021-08-25 ユニヴァーシティー オブ ユタ リサーチ ファウンデーション 免疫寛容及び非免疫寛容エラスチン様組換えペプチドならびに使用方法
WO2016193300A1 (en) 2015-06-01 2016-12-08 Medigene Immunotherapies Gmbh Method for generating antibodies against t cell receptor
NZ737400A (en) 2015-06-01 2019-09-27 Medigene Immunotherapies Gmbh T cell receptor library
CA3004132A1 (en) 2015-11-09 2017-05-18 Immune Design Corp. A retroviral vector for the administration and expression of replicon rna expressing heterologous nucleic acids
SG11201803546WA (en) 2015-11-09 2018-05-30 Immune Design Corp Compositions comprising lentiviral vectors expressing il-12 and methods of use thereof
EP4092112A1 (de) 2015-11-13 2022-11-23 PDS Biotechnology Corporation Lipide als synthetische vektoren zur verbesserung der antigenverarbeitung und präsentation ex-vivo in der dendritischen zelltherapie
SG11201804413XA (en) 2015-11-25 2018-06-28 Academisch Ziekenhuis Leiden Recombinant serine proteases
BR112018012694A2 (pt) 2015-12-23 2018-12-04 Medigene Immunotherapies Gmbh composição de célula dendrítica, vacina de célula dendrítica, composição e kit
EP3443001B1 (de) 2016-04-11 2025-04-30 Obsidian Therapeutics, Inc. Regulierte bioschaltkreissysteme
ES3046711T3 (en) 2016-04-15 2025-12-02 Beckman Coulter Inc Photoactive macromolecules and uses thereof
ES2904269T3 (es) 2016-05-16 2022-04-04 Harvard College Método para la purificación y la activación de la neurotoxina botulínica
EP3494128B1 (de) 2016-08-04 2023-11-29 Stichting VUmc Embryonale angiogenesemarker und darauf basierende diagnostische und therapeutische strategien
KR102780603B1 (ko) 2016-09-16 2025-03-12 라이트하우스 파마슈티컬스, 인코포레이티드 리신 진지파인의 케톤 억제제
CN116693695A (zh) 2017-02-12 2023-09-05 百欧恩泰美国公司 基于hla的方法和组合物及其用途
CN110913954A (zh) 2017-03-03 2020-03-24 黑曜石疗法公司 免疫疗法的组合物和方法
CN110831961B (zh) 2017-03-03 2024-01-02 黑曜石疗法公司 用于免疫疗法的cd19组合物和方法
EP3668309A4 (de) 2017-08-14 2021-06-09 University of Georgia Research Foundation, Inc. Proteine mit pneumokokken-kapsel-abbauender aktivität und verwendungsverfahren
EP3691693A4 (de) 2017-10-06 2021-08-25 University Of Utah Research Foundation Fusionsprotein zur gezielten therapie einer autoimmunerkrankung
AU2018378588A1 (en) 2017-12-05 2020-06-25 Pds Biotechnology Corporation Methods and compositions comprising cationic lipids for stimulating type 1 interferon genes
EP4424710A3 (de) 2018-02-26 2025-01-15 Medigene Immunotherapies GmbH Nyeso-tcr
US20220403001A1 (en) 2018-06-12 2022-12-22 Obsidian Therapeutics, Inc. Pde5 derived regulatory constructs and methods of use in immunotherapy
WO2020030631A1 (en) 2018-08-06 2020-02-13 Medigene Immunotherapies Gmbh Ha-1 specific t cell receptors and their use
WO2020070089A1 (en) 2018-10-01 2020-04-09 Ospedale San Raffaele S.R.L. Chromogranin a and uses thereof
WO2020086742A1 (en) 2018-10-24 2020-04-30 Obsidian Therapeutics, Inc. Er tunable protein regulation
US11584825B2 (en) 2018-12-14 2023-02-21 Beckman Coulter, Inc. Polymer dye modification and applications
AU2019404547B2 (en) 2018-12-21 2025-01-30 Biontech Us Inc. Method and systems for prediction of HLA class II-specific epitopes and characterization of CD4+ T cells
KR20210149251A (ko) 2019-03-08 2021-12-08 옵시디안 테라퓨틱스, 인크. 조율가능한 조절을 위한 인간 탄산 무수화효소 2 조성물 및 방법
EP3714941A1 (de) 2019-03-27 2020-09-30 Medigene Immunotherapies GmbH Mage-a4-tcrs
TWI850360B (zh) 2019-04-04 2024-08-01 德商梅迪基因免疫治療公司 黑色素瘤相關抗原１（ｍａｇｅａ１）特異性ｔ細胞受體及其用途
WO2020252404A1 (en) 2019-06-12 2020-12-17 Obsidian Therapeutics, Inc. Ca2 compositions and methods for tunable regulation
JP2022537670A (ja) 2019-06-12 2022-08-29 オブシディアン セラピューティクス， インコーポレイテッド Ｃａ２の組成物および調整可能な制御方法
EP3997116A1 (de) 2019-07-09 2022-05-18 Medigene Immunotherapies GmbH Magea10-spezifische t-zell-rezeptoren und deren verwendung
WO2021046451A1 (en) 2019-09-06 2021-03-11 Obsidian Therapeutics, Inc. Compositions and methods for dhfr tunable protein regulation
WO2021067741A1 (en) 2019-10-02 2021-04-08 University Of Georgia Research Foundation, Inc. Glycopeptides for inducing an immune response and methods of use
US20230211004A1 (en) 2019-11-22 2023-07-06 University Of Georgia Research Foundation, Inc. Tetanus toxoid and crm-based peptides and methods of use
US20230008380A1 (en) 2019-12-09 2023-01-12 University Of Georgia Research Foundation, Inc. M. tuberculosis ag85 proteins and methods of use
WO2022016035A1 (en) 2020-07-17 2022-01-20 University Of Georgia Research Foundation, Inc. Β-glucuronidase proteins having pneumococcal capsule degrading activity and methods of use
US20230340064A1 (en) 2020-09-24 2023-10-26 Medigene Immunotherapies Gmbh Mage-a3 specific t cell receptors and their use
CN117015711A (zh) 2021-02-05 2023-11-07 贝克曼库尔特有限公司 用于阻止聚合物染料-抗体缀合物之间的非特异性相互作用的组合物和方法
CA3215758A1 (en) 2021-05-07 2022-11-10 Medigene Immunotherapies Gmbh Combination of prame specific t cell receptors and chimeric co-stimulatory receptors
WO2023025779A1 (en) 2021-08-25 2023-03-02 Medigene Immunotherapies Gmbh Combination of antigen specific t cell receptors and chimeric co-stimulatory receptors
US20240400893A1 (en) 2021-09-30 2024-12-05 Beckman Coulter, Inc. Water-soluble tetrahydropyrene based fluorescent polymers
CN119768178A (zh) 2022-08-23 2025-04-04 基因医疗免疫疗法有限责任公司 Ny-eso-1特异性t细胞受体与嵌合共刺激受体的组合
EP4635976A1 (de) 2024-04-19 2025-10-22 Medigene Immunotherapies GmbH Konstante uni-laschen
WO2025219541A1 (en) 2024-04-19 2025-10-23 Medigene Immunotherapies Gmbh Constant uni-tabs

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4468464A (en) * 1974-11-04 1984-08-28 The Board Of Trustees Of The Leland Stanford Junior University Biologically functional molecular chimeras
NO158880C (no) * 1977-11-08 1988-11-09 Genentech Inc Fremgangsmaate for fremstilling av et spesifikt pattedyrhormon.
US4563424A (en) * 1979-11-05 1986-01-07 Genentech, Inc. Method and means for somatostatin protein conjugate expression
US4366246A (en) * 1977-11-08 1982-12-28 Genentech, Inc. Method for microbial polypeptide expression
US4571421A (en) * 1979-11-05 1986-02-18 Genentech, Inc. Mammalian gene for microbial expression
CA1200773A (en) * 1980-02-29 1986-02-18 William J. Rutter Expression linkers
US4532207A (en) * 1982-03-19 1985-07-30 G. D. Searle & Co. Process for the preparation of polypeptides utilizing a charged amino acid polymer and exopeptidase
US4503142A (en) * 1982-06-25 1985-03-05 Litton Bionetics, Inc. Open reading frame vectors
US4559302A (en) * 1982-11-01 1985-12-17 Eli Lilly And Company DNA for directing transcription and expression of structural genes

Also Published As

Publication number Publication date
JPH074255B2 (ja) 1995-01-25
EP0150126A3 (en) 1987-06-03
EP0150126A2 (de) 1985-07-31
DE3584260D1 (de) 1991-11-07
JPS60222429A (ja) 1985-11-07
US4703004A (en) 1987-10-27
EP0150126B1 (de) 1991-10-02

Similar Documents

Publication Publication Date Title
DE3584260D1 (de) Die synthese eines proteins mittels eines identifizierungspeptids.
Sanger Chemistry of insulin: determination of the structure of insulin opens the way to greater understanding of life processes
DK0531404T3 (da) Ubiquitin-specifik protease
Denkewalter et al. Total synthesis of an enzyme. I. Objective and strategy
Watson et al. The amino acid sequence of chymopapain from Carica papaya
Grant et al. Amino acid sequence of a collagenolytic protease from the hepatopancreas of the fiddler crab, Uca pugilator
IE883612L (en) Vectors and compounds for direct expression of activated human protein c
ATE73460T1 (de) Peptide aus alpha-aminoboronsaeuren.
NZ232742A (en) Yeast heterologous protein production method, vectors, dna constructs and proteins so produced and aprotinin (1-58) so produced
ES8500325A1 (es) Procedimiento para la preparacion de proteinas funcionales de uroquinasa humana.
BG60256B1 (bg) Рекомбинантен метод за получаване на лимфотоксин
ES2114539T3 (es) Expresion de polipeptidos recombinados con purificacion mejorada.
ZA8860B (en) Pancreatic secretory trypsin inhibitor and variants thereof produced by a recombinant host,process,expression vector and recombinant host therefor and pharmaceutical use thereof
EP0195680A3 (de) Proteinsynthese mit einem Identifizierungspeptid
Graf et al. Cathepsin D generates γ-endorphin from β-endorphin
Proost et al. Chemical synthesis, purification and folding of the human monocyte chemotactic proteins MCP-2 and MCP-3 into biologically active chemokines
DE69233245D1 (de) Verfahren zur Herstellung von Peptiden
ATE317443T1 (de) N-terminal verlängerte proteine exprimiert in hefe
BR9714133A (pt) ácido nucleico isolado, molécula do mesmo, sonda, vetor de expressão recombinante, célula, polipeptìdeo, proteìna de fusão formulação de vacina e processos para produzir um polipeptìdeo de h. pylori, para detctar a presença de um ácido nucleico de helicobacter em uma amostra, para tratar ou reduzir um risco de infecção por h. pylori em um indivìduo e para produzir uma formulação de vacina
ATE79409T1 (de) Herstellungsverfahren fuer humanes atriales natriuretisches polypeptid.
Limeback et al. Nature of collagens synthesized by monkey periodontal-ligament fibroblasts in vitro
SUGENO et al. The amino acid sequence of cytochrome c from Debaryomyces kloeckeri
KR860006484A (ko) 단백질 또는 당단백질의 제조방법
Desai et al. Carboxyl-terminal sequence of the glycine-arginine-rich histone from bovine lymphosarcoma, Novikoff hepatoma and fetal calf thymus
KR860008282A (ko) 재조합 사람 레닌의 제조방법

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EEIH Change in the person of patent owner
EEIH Change in the person of patent owner
EELA Cancelled due to lapse of time